logo

Morphosys Ag (MOR)



Trade MOR now with
  Date
  Headline
1/9/2023 1:44:49 AM MorphoSys Expects Topline Data From Phase 3 MANIFEST-2 Study Of Pelabresib In Myelofibrosis In Early 2024
1/5/2023 6:21:15 AM MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales Of $89.4 Mln
12/12/2022 12:04:36 AM MorphoSys Presents New Longer-term Phase 2 Results On Pelabresib In Myelofibrosis At ASH
11/16/2022 5:42:55 PM MorphoSys AG Q3 Loss Climbs
11/16/2022 4:06:37 PM MorphoSys Q3 Loss/share EUR 3.60 Vs. Loss EUR 3.30 Year Ago
10/21/2022 9:23:11 AM MorphoSys Sees 2022 Monjuvi U.S. Net Product Sales To Be About $90 Mln
8/3/2022 4:11:03 PM MorphoSys AG Q2 Earnings Summary
7/26/2022 6:16:52 AM MorphoSys Preliminary Q2 Monjuvi U.S. Net Product Sales $23.3 Mln/EUR 21.7 Mln
6/15/2022 8:43:08 AM I-Mab Partner MorphoSys Announces License Agreements For Felzartamab And TJ210
6/14/2022 4:09:51 PM MorphoSys And HIBio Enter Into Equity Participation And License Agreements For Felzartamab And MOR210
6/10/2022 3:30:46 AM MorphoSys Presents Data From Multiple Analyses Of MANIFEST Study